The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
- PMID: 12422218
- DOI: 10.1038/nature01158
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
Abstract
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, which are approved for cholesterol reduction, may also be beneficial in the treatment of inflammatory diseases. Atorvastatin (Lipitor) was tested in chronic and relapsing experimental autoimmune encephalomyelitis, a CD4(+) Th1-mediated central nervous system (CNS) demyelinating disease model of multiple sclerosis. Here we show that oral atorvastatin prevented or reversed chronic and relapsing paralysis. Atorvastatin induced STAT6 phosphorylation and secretion of Th2 cytokines (interleukin (IL)-4, IL-5 and IL-10) and transforming growth factor (TGF)-beta. Conversely, STAT4 phosphorylation was inhibited and secretion of Th1 cytokines (IL-2, IL-12, interferon (IFN)-gamma and tumour necrosis factor (TNF)-alpha) was suppressed. Atorvastatin promoted differentiation of Th0 cells into Th2 cells. In adoptive transfer, these Th2 cells protected recipient mice from EAE induction. Atorvastatin reduced CNS infiltration and major histocompatibility complex (MHC) class II expression. Treatment of microglia inhibited IFN-gamma-inducible transcription at multiple MHC class II transactivator (CIITA) promoters and suppressed class II upregulation. Atorvastatin suppressed IFN-gamma-inducible expression of CD40, CD80 and CD86 co-stimulatory molecules. l-Mevalonate, the product of HMG-CoA reductase, reversed atorvastatin's effects on antigen-presenting cells (APC) and T cells. Atorvastatin treatment of either APC or T cells suppressed antigen-specific T-cell activation. Thus, atorvastatin has pleiotropic immunomodulatory effects involving both APC and T-cell compartments. Statins may be beneficial for multiple sclerosis and other Th1-mediated autoimmune diseases.
Comment in
-
Tackling multiple sclerosis.Nature. 2002 Nov 7;420(6911):39-40. doi: 10.1038/420039a. Nature. 2002. PMID: 12422206 No abstract available.
Similar articles
-
Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats.J Autoimmun. 2005 Dec;25(4):258-63. doi: 10.1016/j.jaut.2005.06.005. Epub 2005 Oct 19. J Autoimmun. 2005. PMID: 16242301
-
Immunoregulatory effects of atorvastatin on experimental autoimmune myocarditis in Lewis rats.Immunol Cell Biol. 2006 Jun;84(3):274-80. doi: 10.1111/j.1440-1711.2006.01430.x. Immunol Cell Biol. 2006. PMID: 16509827
-
Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis.Neurochem Int. 2008 Jul;53(1-2):17-21. doi: 10.1016/j.neuint.2008.04.004. Epub 2008 Apr 20. Neurochem Int. 2008. PMID: 18524417
-
[Effects of atorvastatin in multiple sclerosis].Nihon Rinsho. 2003 Aug;61(8):1455-60. Nihon Rinsho. 2003. PMID: 12962038 Review. Japanese.
-
Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors.Clin Immunol. 2006 Apr;119(1):1-12. doi: 10.1016/j.clim.2005.11.007. Epub 2006 Jan 4. Clin Immunol. 2006. PMID: 16386956 Review.
Cited by
-
Regulation of suppressors of cytokine signaling as a therapeutic approach in autoimmune diseases, with an emphasis on multiple sclerosis.J Signal Transduct. 2011;2011:635721. doi: 10.1155/2011/635721. Epub 2011 Nov 1. J Signal Transduct. 2011. PMID: 22132325 Free PMC article.
-
Chronic urticaria and use of statins.Asia Pac Allergy. 2012 Jul;2(3):227-9. doi: 10.5415/apallergy.2012.2.3.227. Epub 2012 Jul 25. Asia Pac Allergy. 2012. PMID: 22872826 Free PMC article. No abstract available.
-
Hemodynamic effects of peri-operative statin therapy in on-pump cardiac surgery patients.J Cardiothorac Surg. 2012 Jul 13;7:39. doi: 10.1186/1749-8090-7-39. J Cardiothorac Surg. 2012. PMID: 22533985 Free PMC article.
-
Suppression of MOG- and PLP-induced experimental autoimmune encephalomyelitis using a novel multivalent bifunctional peptide inhibitor.J Neuroimmunol. 2013 Oct 15;263(1-2):20-7. doi: 10.1016/j.jneuroim.2013.07.009. Epub 2013 Aug 1. J Neuroimmunol. 2013. PMID: 23911075 Free PMC article.
-
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.BMJ Open. 2024 Sep 16;14(9):e086414. doi: 10.1136/bmjopen-2024-086414. BMJ Open. 2024. PMID: 39284697 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous